Anifrolumab Plus Standard Care Reduces Organ Damage in SLE Patients: Study Results
How Anifrolumab Helps Reduce Organ Damage in Lupus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can cause widespread inflammation and irreversible organ damage. Managing SLE effectively requires controlling disease activity, preventing flares, and minimizing long-term glucocorticoid use.
A recent study compared the effects of anifrolumab plus standard of care (SOC) to real-world external controls receiving SOC alone. The findings suggest that anifrolumab may help reduce organ damage accumulation in patients with moderate to severe SLE.
Key Findings
-
Patients who received anifrolumab plus SOC accumulated significantly less organ damage over 208 weeks than those who received SOC alone.
-
Long-term glucocorticoid use is associated with increased organ damage, making alternative treatment approaches important.
-
These results suggest that adding anifrolumab to SOC could be a more effective long-term treatment strategy for SLE.
Implications for SLE Treatment
Reducing organ damage in SLE is crucial for improving quality of life, reducing healthcare costs, and minimizing mortality risks. This study provides further evidence that anifrolumab may be a valuable option for patients needing better disease control.
